Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $3.7 million.

  • Entrada Therapeutics' Change in Accured Expenses rose 22.97% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 46.99%. This contributed to the annual value of $1.7 million for FY2024, which is 55.19% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Change in Accured Expenses stood at $3.7 million, which was down 13.38% from $4.3 million recorded in Q2 2025.
  • Entrada Therapeutics' Change in Accured Expenses' 5-year high stood at $6.9 million during Q3 2022, with a 5-year trough of -$5.5 million in Q1 2025.
  • Its 3-year average for Change in Accured Expenses is $737,455, with a median of $2.0 million in 2023.
  • Examining YoY changes over the last 5 years, Entrada Therapeutics' Change in Accured Expenses showed a top increase of 369.13% in 2023 and a maximum decrease of 795.59% in 2023.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then spiked by 145.03% to $2.0 million in 2023, then slumped by 121.74% to -$425,000 in 2024, then grew by 22.97% to $3.7 million in 2025.
  • Its Change in Accured Expenses stands at $3.7 million for Q3 2025, versus $4.3 million for Q2 2025 and -$5.5 million for Q1 2025.